2,5-Bis(2,2,2- trifluoroethoxy) Benzoic acid 99%

Founded during the pivotal era of India’s journey to independence, Biosynth has stood as a beacon of innovation and accessibility in healthcare since its inception in 1943. As one of Hyderabad’s pioneering pharmaceutical companies, Biosynth played a significant role in reshaping the pharmaceutical landscape, bringing affordable, high-quality healthcare solutions to the forefront.

Biosynth’s journey began with the production of biological products, specifically focused on injections and vaccinations. The company then transitioned to manufacturing lifesaving TB treatments, notably PAS sodium, an Active Pharmaceutical Ingredient (API) that remains a cornerstone of their product lineup. These early milestones marked Biosynth as one of the foremost pharmaceutical API manufacturers in India, known for its dedication to safety and efficacy.

By the late 1990s, Biosynth expanded its presence globally, establishing itself as a major export house and rapidly advancing into diverse therapeutic areas. This success story continued into 2020, when a new generation of technocrats took the helm, with the vision of elevating Biosynth to a world-class player in the manufacturing of pharmaceutical APIs and intermediates. The focus since has been on developing niche molecules, which to date have not been manufactured in India.